Pathway's New World of Hurt

Wednesday, September 28, 2011

As far as I'm able to see it, the Pathway Genomics business plan comes from the Underpants Gnomes, to wit:

  1. Make large, FDA-flaunting announcement
  2. ???
  3. Profit!

Pathway, you'll recall, was responsible for the Walgreens debacle that helped put DTCG vendors under the hot glare of the regulators. Now they're back for a repeat performance, claiming that FDA has classified their saliva collection tube as Class I, 510(k) exempt.

That might come as a surprise to other saliva collection vendors, who seem to believe that 510(k) clearance is required. That's our interpretation too.

It will be interesting to see what gets published first: the retraction or the warning letter. I expect to see one or the other pretty soon.

 

UPDATE (9/29/11) FDA weighs in: "Registration is not a classification process"

 

Tags: 510(k), Advertising & Promotion, FDA, Public Statements, Warning Letters

Other Blog Authors

Dylan Reinhardt
Dave Kern
Steve Gutman
Jo-Ann Gonzales

Recent Blog Posts

The Staple That Changed an Industry LDT regulation and the perils of challenging Eminem to a rap battle
FDA Releases the Kraken Whichever way this breaks, it's long past time to have this conversation in a meaningful way
Illumina Acquires Myraqa Acquisition Strengthens Illumina’s Clinical Readiness
The Spirit of GLP A Best Practice for IVDs
Process Performance Qualification (PPQ) Lots So, how many lots are required?
The Case for Risk-based Monitoring Better the devil you know...
Form Follows Function OIR Reorganizes to Meet the Advancing Wave of Molecular Diagnostics
CDRH Unveils New PMA Guidance Documents Attention shoppers, it's two-for-one day!